3'-[(6-methyl-2-pyridyl)ethynyl]-2,3-dihydro-3-hydroxy-4'H-spiro[indene-1,5'-isoxazole] | 1354931-00-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 3'-[(6-methyl-2-pyridyl)ethynyl]-2,3-dihydro-3-hydroxy-4'H-spiro[indene-1,5'-isoxazole]
• 英文别名: 3'-[2-(6-methylpyridin-2-yl)ethynyl]spiro[1,2-dihydroindene-3,5'-4H-1,2-oxazole]-1-ol
• CAS: 1354931-00-2
• 化学式: C₁₉H₁₆N₂O₂
• 分子量: 304.348
• InChiKey: IEEFIBGJLNYBDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  54.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS<br/>[FR] NOUVEAUX COMPOSÉS SPIROHÉTÉROCYCLIQUES EN TANT QU'ANTAGONISTES DE MGLU5
  申请人：RECORDATI IRELAND LTD

  公开号：WO2012004400A1

  公开（公告）日：2012-01-12

  The invention provides compounds having the general formula (I) wherein X is O or S; R1 is C, N, O or S; R1a is CH, CH2, N or NH; R2 is a bond, CH or CH2; m is 1, 2 or 3; n is 1 or 2; when n is 2 or m is 2 or 3, the ring containing R1 may be fused with a benzene ring; each --- represents a single or double bond provided that one double bond extends from the carbon atom to which R3-C≡C- is bonded and that no ring carbon atom bears two double bonds; and R3, R4 and R5 represent a wide range of substituents. These compounds are selective for the metabotropic mGlu5 receptor. They, their solvates, hydrates, enantiomers, diastereomers, N-oxides and pharmaceutically acceptable salts, and pharmaceutical compositions containing them, can be used to treat diseases or disorders of the lower urinary tract, especially neuromuscular dysfunctions of the lower urinary tract. They may also be useful for the treatment of migraine; for the treatment of gastroesophageal reflux disease (GERD); for the treatment of anxiety disorder; for the treatment of abuse, substance dependence and substance withdrawal disorder; for the treatment of neuropathic pain disorder; and for the treatment of fragile X syndrome disorders.

  该发明提供了具有一般式（I）的化合物，其中X为O或S；R1为C、N、O或S；R1a为CH、CH2、N或NH；R2为键、CH或 ；m为1、2或3；n为1或2；当n为2或m为2或3时，含有R1的环可能与苯环融合；每个---代表单键或双键，其中一个双键延伸自R3-C≡C-键合的碳原子，且没有环碳原子带有两个双键；R3、R4和R5代表各种取代基。这些化合物对代谢型mGlu5受体具有选择性。它们及其溶剂合物、水合物、对映体、非对映体异构体、N-氧化物和药学上可接受的盐，以及含有它们的药物组合物，可用于治疗下尿路的疾病或紊乱，特别是下尿路的神经肌肉功能紊乱。它们也可能对治疗偏头痛；治疗胃食管反流病（GERD）；治疗焦虑症；治疗滥用、物质依赖和物质戒断紊乱；治疗神经病性疼痛紊乱；以及治疗脆性X综合症紊乱有用。
• NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS
  申请人：Leonardi Amedeo

  公开号：US20120059015A1

  公开（公告）日：2012-03-08

  The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agents for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal. Methods for treating migraine and gastroesophageal reflux disease (GERD) using selective mGlu5 antagonists are also disclosed.

  本发明涉及使用选择性拮抗剂对代谢型mGlu5受体的方法，以治疗哺乳动物下尿道神经肌肉功能障碍的病症。提供了通过给予选择性mGlu5拮抗剂治疗患有下尿道神经肌肉功能障碍的哺乳动物的方法。该选择性mGlu5拮抗剂可以单独或与一种或多种其他治疗剂合并使用以治疗此类病症。还提供了用于治疗偏头痛和胃食管反流病（GERD）的选择性mGlu5拮抗剂的方法。同时还公开了用于鉴定对治疗哺乳动物下尿道神经肌肉功能障碍有用的选择性mGlu5拮抗剂的方法。
• US8580962B2
  申请人：——

  公开号：US8580962B2

  公开（公告）日：2013-11-12